华熙生物：医美、功能性护肤的本质，都在于生命科学对衰老机制的理解及其干预手段探索

Core Viewpoint - Huaxi Biological has made significant improvements in operational quality and profitability since the return of its chairman and general manager in March 2025, despite a decline in revenue [1][2]. Group 1: Financial Performance - In Q3 2025, the net profit attributable to shareholders reached 0.32 billion yuan, a year-on-year increase of 55.63% [1]. - The operating revenue was 9.03 billion yuan, showing a year-on-year decline of 15.16% [1]. - The net cash flow from operating activities increased by 8.59 times year-on-year, indicating continuous improvement in core indicators [1]. Group 2: Strategic Focus - The company is focusing on a comprehensive business layout in the field of aging intervention, integrating solutions across pharmaceuticals, medical aesthetics, nutritional science, and skin science [2]. - Huaxi Biological aims to upgrade from "Chinese manufacturing" to "Chinese cutting-edge R&D + Chinese brands" by expanding its industrial ecosystem around core life science materials [2]. - The growth points for the company are derived from its integration capabilities in three areas: stability and regeneration of extracellular matrix (ECM), maintenance of cellular energy and function, and precise regulation of intercellular information transmission [2].